Canadian team tests new combo for failing hearts
NCT ID NCT06570473
Summary
This study is testing if adding one of two existing drugs (empagliflozin or ranolazine) to standard care helps people with right-sided heart failure caused by high lung blood pressure. It will enroll 30 adults to see if this approach is practical for a larger future trial. The main goal is to check if the study process itself works, while also measuring changes in heart function and symptoms over 16 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIGHT VENTRICULAR DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
London Health Sciences Centre - University Hospital
NOT_YET_RECRUITINGLondon, Ontario, N6A 5A5, Canada
-
The Ottawa Hospital
NOT_YET_RECRUITINGOttawa, Ontario, K1Y 4E9, Canada
-
The University of British Columbia
NOT_YET_RECRUITINGVancouver, British Columbia, V5Z 1M9, Canada
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G 2G3, Canada
-
University of Calgary
NOT_YET_RECRUITINGCalgary, Alberta, T1Y 6J4, Canada
Conditions
Explore the condition pages connected to this study.